Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate

The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized X...

Descripción completa

Detalles Bibliográficos
Autores principales: Uraki, Ryuta, Ito, Mutsumi, Kiso, Maki, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Sakai-Tagawa, Yuko, Imai, Masaki, Koga, Michiko, Yamamoto, Shinya, Adachi, Eisuke, Saito, Makoto, Tsutsumi, Takeya, Otani, Amato, Fukushi, Shuetsu, Watanabe, Shinji, Suzuki, Tadaki, Kikuchi, Tetsuhiro, Yotsuyanagi, Hiroshi, Maeda, Ken, Kawaoka, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590837/
https://www.ncbi.nlm.nih.gov/pubmed/37876803
http://dx.doi.org/10.1016/j.isci.2023.108147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590837/
https://www.ncbi.nlm.nih.gov/pubmed/37876803
http://dx.doi.org/10.1016/j.isci.2023.108147

Ejemplares similares